6CM
ATXS

683 Capital Management’s Astria Therapeutics ATXS Stock Holding History

683 Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,718
Closed -$219K – 305
2022
Q4 		$219K Buy
+14,718
New +$152K 0.02% 151

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

683 Capital Management's ATXS Position: Q1 2023 in Review

683 Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2023, closing a stake of 14,718 shares — an estimated $219K sold.

683 Capital Management first reported a position in ATXS in Q4 2022 and held it in 1 quarter. The position peaked at $219K in Q4 2022. 65 funds tracked by Wall St. Rank hold ATXS as of Q1 2023.

  • 683 Capital Management reported no remaining Astria Therapeutics position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 14,718 Astria Therapeutics shares in Q1 2023, an estimated $219K.
  • 683 Capital Management first reported a position in Astria Therapeutics in Q4 2022 and held it in 1 quarter.
  • 683 Capital Management's Astria Therapeutics position peaked at $219K in Q4 2022.
  • 65 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.